

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID: SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1			Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31		IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31		CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31		CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31		LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31		EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04		STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15		WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28		EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28		IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30		INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30		DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06		EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06		KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13		USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19		CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25		CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30		AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30		EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30		STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30		STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28		CA/CAplus patent coverage enhanced
NEWS 23	JUL 28		EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28		IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28		STN Viewer performance improved
NEWS 26	AUG 01		INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27	AUG 13		CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 28	AUG 15		CAOLD to be discontinued on December 31, 2008
NEWS 29	AUG 15		CAplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3.

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:57:38 ON 21 AUG 2008

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
SESSION
FULL ESTIMATED COST ENTRY SESSION 0.21 0.21

FILE 'MEDLINE' ENTERED AT 10:57:59 ON 21 AUG 2008

FILE 'EMBASE' ENTERED AT 10:57:59 ON 21 AUG 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:57:59 ON 21 AUG 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:57:59 ON 21 AUG 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:57:59 ON 21 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s CD23

=> s 11 and binding peptide
L2 1 L1 AND BINDING PEPTIDE

=> d 12 chib abs

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
2005:1130891 Document No. 143:399818 CD23-binding
peptides and peptidomimetics for treatment of autoimmune and
inflammatory disorders. Mossalayi, Mohammad Djavad; Moynet, Daniel;
Vincendeau, Philippe; Rambert, Jerome; Self, Christopher R. (Universite
Bordeaux 2, Fr.). PCT Int. Appl. WO 2005098435 A2 20051020, 59 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ,
CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU,
MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2005-IB1133 20050405. PRIORITY: EP 2004-290899 20040405.

AB The invention describes compds. comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compds. of the invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1-X2- X3-X4-X5-X6-X7-X8, wherein: X1 is Phe, or is absent; X2 is His or Ala; X3 is Glu, Ser, Ala, Asn, Lys, or Cys; X4 is Asn, Phe, Gln, Pro, Ser, or Ala; X5 is Trp; X6 is Pro, Arg, Glu, Gly, Cys, or Lys; X7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8 is Phe, Gly, or is absent. Treatment of arthritic rats with peptide p30A resulted in remission of the arthritic condition and produced weight gain.

=> s phage display
L3 23469 PHAGE DISPLAY

=> s l3 and CD23
L4 5 L3 AND CD23

=> dup remove 14
PROCESSING COMPLETED FOR L4
L5 5 DUP REMOVE L4 (0 DUPLICATES REMOVED)

=> d 15 1-5 cbib abs

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
2005:1130891 Document No. 143:399818 CD23-binding peptides and peptidomimetics for treatment of autoimmune and inflammatory disorders. Mossalayi, Mohammad Djavad; Moynet, Daniel; Vincendeau, Philippe; Rambert, Jerome; Self, Christopher R. (Universite Bordeaux 2, Fr.). PCT Int. Appl. WO 2005098435 A2 20051020, 59 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-IB1133 20050405. PRIORITY: EP 2004-290899 20040405.

AB The invention describes compds. comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compds. of the invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1-X2- X3-X4-X5-X6-X7-X8, wherein: X1 is Phe, or is absent; X2 is His or Ala; X3 is Glu, Ser, Ala, Asn, Lys, or Cys; X4 is Asn, Phe, Gln, Pro, Ser, or Ala; X5 is Trp; X6 is Pro, Arg, Glu, Gly, Cys, or Lys; X7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8 is Phe, Gly, or is absent. Treatment of arthritic rats with peptide p30A resulted in remission of the arthritic condition and produced weight gain.

L5 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
2006:137443 Document No.: PREV200600133456. A novel anti CD23 fully human monoclonal antibody potentially useful for B-CLL therapy. Delcommenne, Marc [Reprint Author]; Klingemann, Hans-Georg; Gregory, Stephanie A.. Tufts New England Med Ctr, Div Hematol Oncol, Boston, MA USA. Blood, (NOV 16 2005) Vol. 106, No. 11, Part 2, pp. 343B.

Meeting Info.: 47th Annual Meeting of the American-Society-of-Hematology.
Atlanta, GA, USA. December 10 -13, 2005. Amer Soc Hematol.

CODEN: BLOOAW. ISSN: 0006-4971. Language: English.

AB B-cell chronic lymphocytic leukemia (B-CLL) is one of the most common hematological malignancies and is, in most cases, characterized by an increased expression of CD23 on the cell surface. Since cross-linking CD23 induces B-CLL apoptosis, it is an attractive target for B-CLL antibody-based immunotherapy. In this study we show that an anti-CD23 human IgG1 monoclonal antibody, C6F5, may be useful in treating B-CLL. This antibody is derived from the human single chain antibody (scFv) C6F5 that was originally raised against the RPMI-8226 multiple myeloma cell line using the antibody phage display technique. While the C6F5 scFv did not bind to other myeloma cell lines, it was able to bind weakly to normal peripheral blood B lymphocytes and strongly to EBV transformed B cells and B-CLL cells. The antigen recognized by C6F5 was also upregulated on B lymphocytes that had been stimulated by CD40 ligand. Immunoprecipitations by the scFv C6F5 identified a protein of 45 kDa which co-migrated with CD23. Furthermore, this protein was recognized by an anti-CD23 mouse mAb in Western blot analyses. Immunofluorescence staining with the C6F5 scFv was inhibited if cells were preincubated with an anti-CD23 polyclonal antiserum. Taken together, these results verify that C6F5 recognizes CD23. The V. and V_h regions of C6F5 antibody were then cloned into a baculovirus transfer vector encoding the human IgG(1) heavy and light chains so that fully human C6F5 IgG(1) antibody could be produced in baculovirus infected SF9 cells. Since C6F5 binding specificity was preserved in the IgG(1) format, this antibody is ready to be tested in in vitro cytotoxic assays against B-CLL cells.

L5 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

2005098013 EMBASE Antibody Engineering - IBC's 15th Annual International Conference. 30 November - 3 December 2004, San Diego, CA, USA.
Haurum, John S. (correspondence). Symphogen A/S, Elektrovej, Building 375, DK-2800 Lyngby, Denmark. jh@symphegen.com.
IDrugs Vol. 8, No. 2, pp. 91-93 Feb 2005.
ISSN: 1369-7056. CODEN: IDRUFN
Pub. Country: United Kingdom. Language: English.
Entered STN: 20050317. Last Updated on STN: 20050317

L5 ANSWER 4 OF 5 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN

2004:807448 The Genuine Article (R) Number: 849UH. Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and *Humicola lanuginosa* lipase from combinatorial phage libraries. Jakobsen C G (Reprint); Bodtger U; Kristensen P; Poulsen L K; Roggen E L. Novozymes AS, Prot Screening, Smoermosevej 11, 6E2-03, 11, DK-2880 Bagsvaerd, Denmark (Reprint); Novozymes AS, Prot Screening, DK-2880 Bagsvaerd, Denmark; Univ Aarhus, Dept Biol Mol, DK-8000 Aarhus C, Denmark; Natl Univ Hosp, Allergy Clin, DK-2100 Copenhagen, Denmark. cgjakobsen@health.sdu.dk. MOLECULAR IMMUNOLOGY (AUG 2004) Vol. 41, No. 10, pp. 941-953. ISSN: 0161-5890.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND. Language: English.
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Allergen-specific Fab fragments isolated from combinatorial IgE and IgG libraries are useful tools for studying allergen-antibody interactions. To characterise the interaction between different allergens and antibodies we have created recombinant human phage antibody libraries in the Fab format. Human IgE and IgG libraries have been created from patients allergic to birch pollen or lipase. These libraries have been used to select binders recognising the major birch pollen allergen Bet v 1 and *Humicola lanuginosa* lipase. A panel of allergen-specific IgE and IgG

antibodies were identified; these were further characterised by allergen binding studies using Biacore and competition studies using human sera and antibodies purified from human sera. Affinities in the nM range were recorded and a competition with human sera for allergen binding was observed. (C) 2004 Elsevier Ltd. All rights reserved.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
2002:575207 Document No. 137:139379 Chronic lymphocytic leukemia (CLL) cell line CLL-AAT and its use in the prepn. and characterization of anti-CLL antibodies. Bowdish, Katherine S.; McWhirter, John (Alexion Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2002059280 A2 20020801, 35 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US47931 20011210. PRIORITY: US 2000-254113P 20001208.

AB A CLL line, CLL-AAT, and the preparation and characterization of antibodies using said cell line is disclosed. CLL-AAT is derived from a B-CLL primary cell and not established by immortalization with EBV. The cell line is characterized by immunophenotyping and shown to have high expression of IgM, kappa light chain, CD23, CD38, and CD138, moderate expression of CD19 and CD20, and weak expression of IgD and CD5. The cell line was neg. for lambda light chain, CD4, CD8, and CD10. It also recognizes a panel of rabbit scFv antibodies that had been selected for specific binding to primary B-CLL cells. In a further aspect, the CLL-AAT cell line is used to generate monoclonal antibodies useful in the diagnosis and/or treatment of CLL. In a still further aspect, antibodies may be generated by panning antibody libraries using primary CLL cells, or antigens derived therefrom, and further screened and/or characterized using the cell line of the invention. More particularly, 25 synthetic rabbit scFv antibodies specific for CLL are isolated and characterized.

=> s peptide

L6 2001942 PEPTIDE

=> s 16 and "HENWPS"

L7 0 L6 AND "HENWPS"

=> s 16 and "FHENWES"

L8 0 L6 AND "FHENWES"

=> s 16 and CD23

L9 308 L6 AND CD23

=> s 19 and "FHENWP"

L10 0 L9 AND "FHENWP"

=> s 19 and "FHENWPT"

L11 0 L9 AND "FHENWPT"

=> s 19 and "p30A"

L12 1 L9 AND "P30A"

=> d 112 cbib abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

2005:1130891 Document No. 143:399818 CD23-binding peptides

and peptidomimetics for treatment of autoimmune and inflammatory disorders. Mossalayi, Mohammad Djavad; Moynet, Daniel; Vincendeau, Philippe; Rambert, Jerome; Self, Christopher R. (Universite Bordeaux 2, Fr.). PCT Int. Appl. WO 2005098435 A2 20051020, 59 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2005-IB1133 20050405. PRIORITY: EP 2004-290899 20040405.

AB The invention describes compds. comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compds. of the invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1-X2-X3-X4-X5-X6-X7-X8, wherein: X1 is Phe, or is absent; X2 is His or Ala; X3 is Glu, Ser, Ala, Asn, Lys, or Cys; X4 is Asn, Phe, Gln, Pro, Ser, or Ala; X5 is Trp; X6 is Pro, Arg, Glu, Gly, Cys, or Lys; X7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8 is Phe, Gly, or is absent. Treatment of arthritic rats with peptide p30A resulted in remission of the arthritic condition and produced weight gain.

```
=> s CD23 binding peptide
L13          1 CD23 BINDING PEPTIDE

=> s "FHENWPS"
L14          15 "FHENWPS"

=> dup remove 114
PROCESSING COMPLETED FOR L14
L15          3 DUP REMOVE L14 (12 DUPLICATES REMOVED)

=> d 115 1-3 cbib abs
```

```
L15 ANSWER 1 OF 3      MEDLINE on STN          DUPLICATE 1
2008042890.  PubMed ID: 17972282.  A recombinant triblock protein polymer
with dispersant and binding properties for digital printing. Qi Min;
O'Brien John P; Yang Jianjun. (DuPont Central Research and Development,
Experimental Station, Wilmington, DE 19880-0402, USA. ) Biopolymers,
(2008) Vol. 90, No. 1, pp. 28-36. Journal code: 0372525. ISSN: 0006-3525.
Pub. country: United States. Language: English.
```

AB A structured triblock protein was designed to explore the potential of engineered peptides to function as high-performance ink dispersants and binders. The protein consists of three functional elements, including a pigment binding domain, a hydrophilic linker, and a printing surface binding domain. To construct such a chimeric protein, a carbon black binding peptide, FHENWPS, and a cellulose binding peptide, THKTSTQRLLAA, were identified from phage display libraries through biopanning, based on their strong and specific binding affinities to carbon black and cellulose. They were used as carbon black and cellulose binding domains, respectively, in a recombinant triblock protein. A linker sequence, PTPTPTPTPTPTPTPTPT, was adapted from endoglucanase A of the bacterium Cellulomonas fimi, as a small, rigid, and hydrophilic interdomain linker. When incorporated into the triblock structure between the carbon black and cellulose binding sequences, the linker sufficiently isolates these two elements and allows dual binding activity. The

structured triblock protein was shown to disperse carbon black particles and attach it to paper surfaces. Thus, the utility of structured proteins having useful dispersant and binding properties for digital printing inks was demonstrated.

(c) 2007 Wiley Periodicals, Inc.

L15 ANSWER 2 OF 3 MEDLINE on STN DUPLICATE 2
2004376428. PubMed ID: 15279884. Peptides binding to a Gb3 mimic selected from a phage library. Miura Yoshiko; Sasao Yuuki; Kamihira Masamichi; Sakaki Akio; Iijima Shinji; Kobayashi Kazukiyo. (Department of Molecular Design and Engineering, Graduate School of Engineering, Nagoya University, Chikusa, Nagoya 464-8603, Japan.. miuray@mol.nagoya-u.ac.jp) . Biochimica et biophysica acta, (2004 Aug 4) Vol. 1673, No. 3, pp. 131-8. Journal code: 0217513. ISSN: 0006-3002. Pub. country: Netherlands. Language: English.

AB Peptides binding to a Gb3 mimic were selected from 12-mer peptide library. The self-assembled monolayer (SAM) of a Gb3 mimic was formed on the gold surface, and biopanning was carried out with the phage display peptide library. After three rounds of biopanning, four individual sequences were obtained from 10 phage clones, and the selected peptides having the specific 7-mer sequence (FHENWPS) showed affinities to the Gb3 mimic as strong as to RCA120. Molecular dynamics calculations suggested that the peptides bound to the Gb3 mimic by hydrophobic interaction and hydrogen bonding formation, and the cooperative interactions played an important role in the recognition. The Stx-1 binding was inhibited by the peptides.

L15 ANSWER 3 OF 3 MEDLINE on STN DUPLICATE 3
2001467580. PubMed ID: 11479280. Peptides that mimic Candida albicans-derived beta-1,2-linked mannosides. Jouault T; Fradin C; Dzierszinski F; Borg-Von-Zepelin M; Tomavo S; Corman R; Trinel P A; Kerckaert J P; Poulain D. (Laboratoire de Mycologie Fondamentale et Appliquee, INSERM EPI 9915, Universite de Lille II, Faculte de Medecine H. Warembourg, Pole Recherche, Place Verdun, 59037 Lille Cedex, France.) Glycobiology, (2001 Aug) Vol. 11, No. 8, pp. 693-701. Journal code: 9104124. ISSN: 0959-6658. Pub. country: England: United Kingdom. Language: English.

AB Beta-1,2-linked mannosides from Candida albicans phosphopeptidomannan (PPM) bind to macrophages through a receptor independent from the macrophage alpha-linked mannose receptor and stimulate these cells to secrete immune mediators. Anti-beta-1,2-linked mannoside but not anti-alpha-linked mannoside antibodies produced after immunization with neoglycoproteins protect animals from disseminated candidiasis. In this study, peptides that mimic beta-1,2-linked mannosides were isolated using phage display methodology. A phage library expressing random peptides was panned with an anti-beta-1,2-linked mannoside monoclonal antibody (mAb). After three rounds of biopanning, the isolated phages were able to inhibit recognition of C. albicans by the mAb. Sixty percent of the phages had an identical DNA insert corresponding to the peptide sequence FHENWPS that was recognized specifically by the mAb. Injection of KLH-coupled peptide into mice generated high titers of polyclonal antibodies against C. albicans yeast cell walls. The anti-FHENWPS antibodies bound to C. albicans PPM and were inhibited by soluble beta-1,2-mannotetraose. Together, these data provide evidence for mimotopic activity of the peptide selected by biopanning with the anti-beta-1,2-oligomannoside mAb.

=> s "AcwnCOOH"
L16 0 "ACWNCOOH"

=> s "NW"
L17 31830 "NW"

=> s 117 and acylated
L18 8 L17 AND ACYLATED

=> dup remove 118
PROCESSING COMPLETED FOR L18
L19 4 DUP REMOVE L18 (4 DUPLICATES REMOVED)

=> d 119 1-4 cbib abs

L19 ANSWER 1 OF 4 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
2008:413086 The Genuine Article (R) Number: 271YA. Meal-related changes in ghrelin, peptide YY, and appetite in normal weight and overweight children . Lomenick, Jefferson P. (Reprint); Clasey, Jody L.; Anderson, James W.. Univ Kentucky, Div Endocrinol, Dept Pediat, Lexington, KY 40536 USA (Reprint); Univ Kentucky, Dept Kinesiol & Hlth Promot, Lexington, KY USA; Univ Kentucky, Div Endocrinol & Mol Med, Dept Internal Med, Lexington, KY USA. jplome2@email.uky.edu. OBESITY (MAR 2008) Vol. 16, No. 3, pp. 547-552 . ISSN: 1930-7381. Publisher: NATURE PUBLISHING GROUP, 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA. Language: English.

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB objective: Ghrelin and peptide YY (PYY) are two gut hormones that have effects on appetite. Our objectives were to characterize the patterns of secretion of these hormones in response to feeding in school-age children and determine whether there were differences between normal weight (NW) and overweight (OW) subjects.

Methods and Procedures: This was a cross-sectional study at one tertiary care center. Subjects were 7- to 11-year-old healthy NW and OW volunteers recruited from local advertisements. Following an overnight fast, the subjects were given a standardized breakfast and lunch and had nine hourly blood samples for total ghrelin and total PYY. We assessed whether ghrelin and PYY levels changed from the preprandial to postprandial state and corresponded to reported hunger/satiety.

Results: Hunger ratings were similar between the two groups throughout the study period. Ghrelin was not suppressed after eating, did not rise prior to the next meal, and did not correspond to hunger ratings in either group. PYY increased postprandially and decreased preprandially in the NW group, but OW children exhibited this pattern for only part of the day. PYY levels incompletely corresponded to reported satiety in the OW group.

Discussion: Mixed meal consumption had little effect on ghrelin secretion and a variable effect on PYY secretion in young children in our study. Differences that were observed between the groups do not suggest that an abnormality in their secretion contributes to the development of obesity.

L19 ANSWER 2 OF 4 MEDLINE on STN DUPLICATE 1
2007106622. PubMed ID: 17119003. Regulation of appetite in lean and obese adolescents after exercise: role of acylated and desacyl ghrelin. Mackelvie Kerry J; Meneilly Graydon S; Elahi Dariush; Wong Alfred C K; Barr Susan I; Chanoine Jean-Pierre. (Endocrinology and Diabetes Unit, Room K4-212, British Columbia's Children's Hospital, 4480 Oak Street, Vancouver, British Columbia, Canada V6H 3V4.) The Journal of clinical endocrinology and metabolism, (2007 Feb) Vol. 92, No. 2, pp. 648-54. Electronic Publication: 2006-11-21. Journal code: 0375362. ISSN: 0021-972X. Pub. country: United States. Language: English.

AB CONTEXT: Increased physical activity is an integral part of weight loss programs in adolescents. We hypothesized that exercise could affect appetite-regulating hormones and the subjective desire to eat, which could partly explain the poor success rate of the existing interventions.

OBJECTIVE: The objective of this study was to investigate prospectively

the effects of exercise on acylated ghrelin (AG) and desacyl ghrelin (DG) concentrations and on appetite. SETTING: The setting for this study was a tertiary care center. PARTICIPANTS: Normal-weight [NW; body mass index (mean +/- se), 20.7 +/- 0.5 kg/m²] and overweight (OW; body mass index, 32.4 +/- 1.7) male adolescents (n = 17/group, age 15.3 +/- 0.2 yr) were studied. INTERVENTION: Those studied participated in 5 consecutive days of aerobic exercise (1 h/d). MAIN OUTCOME: Changes in AG and DG concentrations and in appetite during a test meal were studied. RESULTS: Exercise did not significantly affect insulin sensitivity or body weight. Fasting total (AG and DG) ghrelin concentrations were lower in OW (600 +/- 33 pg/ml) compared with NW (764 +/- 33 pg/ml, P < 0.05) boys and were not affected by exercise. In contrast, there was a differential effect of exercise on both AG and DG (P < or = 0.019). AG significantly increased after exercise, and this increase was greater in NW compared with OW adolescents (P < 0.05). Higher AG concentrations were correlated with an increase in markers of appetite (P < 0.05). CONCLUSION: Exercise differentially affects AG and DG in NW and OW male adolescents. Our data suggest that total ghrelin does not adequately reflect AG and DG concentrations and that the influence of exercise-induced hormonal changes should be considered to ensure success in weight management.

L19 ANSWER 3 OF 4 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN 1992:114828 Document No.: PREV199293060628; BA93:60628. PLATINUM-II AND PALLADIUM-II COMPLEXES OF SELECTIVELY ACYLATED 1,2,4-BUTANETRIAMINES. ALTMAN J [Reprint author]; SCHUMANN E; KARAGHIOSOFF K; EICHIN-KARAGHIOSOFF E; BECK W. INST ANORGANISCHCEH CHEM, UNIV MUENCHEN, MEISERSTRASSE 1, D-8000 MUENCHEN 2. Zeitschrift fuer Naturforschung Section B Chemical Sciences, (1991) Vol. 46, No. 11, pp. 1473-1488. CODEN: ZNBSEN. ISSN: 0932-0776. Language: ENGLISH.

AB New N1,N2-di-Boc-N4-acyl-1,2,4-butanetriamines 5 (acyl = acetyl, trifluoroacetyl, benzoyl, carboxycyclohexyl, caproyl, carboxycyclobutyl) have been prepared by ring cleavage acylation of Nw-acylated histamines with di-tert-butyl dicarbonate, and reduction with Raney nickel. Free vicinal diamines 6 were generated by acidic removal of Boc-protecting groups and transformed into dichloroplatinum(II) 7 and dichloropalladium(II) complexes 8. By basic treatment of the N1,N2-di-Boc-N4-trifluoroacetyl-1,2,4-butanetriamine 5b the protecting group was removed from the terminal amine to give N1,N2-di-Boc-1,2,4-butanetriamine 9 which forms cis-dichloroplatinum(II) and palladium(II) complexes 10, 11. The compounds have been characterized by IR, NMR (1H, 13C) spectroscopy and elemental analysis, and the structures of the trifluoroacetyl compounds confirmed by 1H 13C and 1H 1H 2D NMR spectroscopy.

L19 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN 1973:500451 Document No. 79:100451 Original Reference No. 79:16239a, 16242a Site of action of new antiviral amino acid analogs. Seto, Y.; Nakamura, Y.; Shimamura, Y.; Toyoshima, S. (Sch. Med., Keio Univ., Tokyo, Japan). Advan. Antimicrob. Antineoplastic Chemother., Proc. Int. Congr. Chemother., 7th, Meeting Date 1971, Volume 1, Issue 1, 351-3. Editor(s): Hejzlar, Miroslav. Univ. Park Press: Baltimore, Md. (English) 1972. CODEN: 26QZAP.

AB Of 300 new amino acid analogues screened against A2/Adachi, A/NWS, and B/Lee virus strains in chick embryo fibroblast cells and in mice as possible antiinfluenza agents, (N-naphthylaminomethylphenylalanine) (I) [41204-83-5], A-206 (N-lauroylphenylalanine) [14379-64-7], and an unidentified compound were effective against the A2/Adachi strain and in mice. I and A-206 were effective against influenza B virus. These analogues did not inhibit viral absorption or release, and did not inactivate viral infectivity. They may inhibit RNA synthesis in infected cells.

=> s 118 and acetylated
L20 0 L18 AND ACETYLATED

=> s 118 and amidated
L21 0 L18 AND AMIDATED

=> s "FHENWP"
L22 15 "FHENWP"

=> dup remove 122
PROCESSING COMPLETED FOR L22
L23 3 DUP REMOVE L22 (12 DUPLICATES REMOVED)

=> d 123 1-3 cbib abs

L23 ANSWER 1 OF 3 MEDLINE on STN DUPLICATE 1
2008042890. PubMed ID: 17972282. A recombinant triblock protein polymer with dispersant and binding properties for digital printing. Qi Min; O'Brien John P; Yang Jianjun. (DuPont Central Research and Development, Experimental Station, Wilmington, DE 19880-0402, USA.) Biopolymers, (2008) Vol. 90, No. 1, pp. 28-36. Journal code: 0372525. ISSN: 0006-3525. Pub. country: United States. Language: English.

AB A structured triblock protein was designed to explore the potential of engineered peptides to function as high-performance ink dispersants and binders. The protein consists of three functional elements, including a pigment binding domain, a hydrophilic linker, and a printing surface binding domain. To construct such a chimeric protein, a carbon black binding peptide, FHENWPS, and a cellulose binding peptide, THKTSTQRLLAA, were identified from phage display libraries through biopanning, based on their strong and specific binding affinities to carbon black and cellulose. They were used as carbon black and cellulose binding domains, respectively, in a recombinant triblock protein. A linker sequence, PTPTPTPTPTPTPTPTPTPT, was adapted from endoglucanase A of the bacterium Cellulomonas fimi, as a small, rigid, and hydrophilic interdomain linker. When incorporated into the triblock structure between the carbon black and cellulose binding sequences, the linker sufficiently isolates these two elements and allows dual binding activity. The structured triblock protein was shown to disperse carbon black particles and attach it to paper surfaces. Thus, the utility of structured proteins having useful dispersant and binding properties for digital printing inks was demonstrated.

(c) 2007 Wiley Periodicals, Inc.

L23 ANSWER 2 OF 3 MEDLINE on STN DUPLICATE 2
2004376428. PubMed ID: 15279884. Peptides binding to a Gb3 mimic selected from a phage library. Miura Yoshiko; Sasao Yuuki; Kamihira Masamichi; Sakaki Akio; Iijima Shinji; Kobayashi Kazukiyo. (Department of Molecular Design and Engineering, Graduate School of Engineering, Nagoya University, Chikusa, Nagoya 464-8603, Japan.. miuray@mol.nagoya-u.ac.jp) . Biochimica et biophysica acta, (2004 Aug 4) Vol. 1673, No. 3, pp. 131-8. Journal code: 0217513. ISSN: 0006-3002. Pub. country: Netherlands. Language: English.

AB Peptides binding to a Gb3 mimic were selected from 12-mer peptide library. The self-assembled monolayer (SAM) of a Gb3 mimic was formed on the gold surface, and biopanning was carried out with the phage display peptide library. After three rounds of biopanning, four individual sequences were obtained from 10 phage clones, and the selected peptides having the specific 7-mer sequence (FHENWPS) showed affinities to the Gb3 mimic as strong as to RCA120. Molecular dynamics calculations suggested that the peptides bound to the Gb3 mimic by hydrophobic interaction and

hydrogen bonding formation, and the cooperative interactions played an important role in the recognition. The Stx-1 binding was inhibited by the peptides.

L23 ANSWER 3 OF 3 MEDLINE on STN DUPLICATE 3
2001467580. PubMed ID: 11479280. Peptides that mimic Candida albicans-derived beta-1,2-linked mannosides. Jouault T; Fradin C; Dzierszinski F; Borg-Von-Zepelin M; Tomavo S; Corman R; Trinel P A; Kerckaert J P; Poulaing D. (Laboratoire de Mycologie Fondamentale et Appliquee, INSERM EPI 9915, Universite de Lille II, Faculte de Medecine H. Warembois, Pole Recherche, Place Verdun, 59037 Lille Cedex, France.) Glycobiology, (2001 Aug) Vol. 11, No. 8, pp. 693-701. Journal code: 9104124. ISSN: 0959-6658. Pub. country: England: United Kingdom. Language: English.

AB Beta-1,2-linked mannosides from Candida albicans phosphopeptidomannan (PPM) bind to macrophages through a receptor independent from the macrophage alpha-linked mannose receptor and stimulate these cells to secrete immune mediators. Anti-beta-1,2-linked mannoside but not anti-alpha-linked mannoside antibodies produced after immunization with neoglycoproteins protect animals from disseminated candidiasis. In this study, peptides that mimic beta-1,2-linked mannosides were isolated using phage display methodology. A phage library expressing random peptides was panned with an anti-beta-1,2-linked mannoside monoclonal antibody (mAb). After three rounds of biopanning, the isolated phages were able to inhibit recognition of C. albicans by the mAb. Sixty percent of the phages had an identical DNA insert corresponding to the peptide sequence FHENWPS that was recognized specifically by the mAb. Injection of KLH-coupled peptide into mice generated high titers of polyclonal antibodies against C. albicans yeast cell walls. The anti-FHENWPS antibodies bound to C. albicans PPM and were inhibited by soluble beta-1,2-mannotetraose. Together, these data provide evidence for mimotopic activity of the peptide selected by biopanning with the anti-beta-1,2-oligomannoside mAb.

```
=> s "HENWS?"  
L24          0 "HENWS?"  
  
=> s "HENWGS?"  
L25          0 "HENWGS"  
  
=> s "FHEQWPS"  
L26          0 "FHEQWPS"  
  
=> s "HENWPS"  
L27          0 "HENWPS"  
  
=> s "HENWKS"  
L28          0 "HENWKS"  
  
=> s "FHEFWPT"  
L29          0 "FHEFWPT"  
  
=> s "FHSQWPN"  
L30          0 "FHSQWPN"  
  
=> s "HENAPS"  
L31          0 "HENAPS"  
  
=> s "HENWES"  
L32          0 "HENWES"  
  
=> s "HENWS"
```

L33 0 "HENWS"
=> s "FHKPWRA"
L34 0 "FHKPWRA"
=> s "FHEQWPS"
L35 0 "FHEQWPS"
=> s cyclic peptide
L36 16323 CYCLIC PEPTIDE
=> s l36 and CD23
L37 0 L36 AND CD23
=> s l36 and binding CD23
L38 0 L36 AND BINDING CD23
=> s l36 and binding
L39 3847 L36 AND BINDING
=> s l39 and CD23
L40 0 L39 AND CD23
=> s "FHENWPA"
L41 0 "FHENWPA"
=> (mossalayi m?/au or moynet d?/au or vincendeau p?/au or rambert j?/au or self c?/au)
(MOSSALAYI IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
=> s (mossalayi m?/au or moynet d?/au or vincendeau p?/au or rambert j?/au or self c?/au)
L42 1291 (MOSSALAYI M?/AU OR MOYNET D?/AU OR VINCENDEAU P?/AU OR RAMBERT J?/AU OR SELF C?/AU)
=> s l42 and peptide
L43 86 L42 AND PEPTIDE
=> s l43 and CD23
L44 1 L43 AND CD23
=> d l44 cbib abs
L44 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
2005:1130891 Document No. 143:399818 CD23-binding peptides
and peptidomimetics for treatment of autoimmune and inflammatory
disorders. Mossalayi, Mohammad Djavad; Moynet, Daniel
; Vincendeau, Philippe; Rambert, Jerome; Self,
Christopher R. (Universite Bordeaux 2, Fr.). PCT Int. Appl. WO
2005098435 A2 20051020, 59 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT,
AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,
DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI,
FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG,
TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-IB1133 20050405.
PRIORITY: EP 2004-290899 20040405.

AB The invention describes compds. comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compds. of the invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1-X2-X3-X4-X5-X6-X7-X8, wherein: X1 is Phe, or is absent; X2 is His or Ala; X3 is Glu, Ser, Ala, Asn, Lys, or Cys; X4 is Asn, Phe, Gln, Pro, Ser, or Ala; X5 is Trp; X6 is Pro, Arg, Glu, Gly, Cys, or Lys; X7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8 is Phe, Gly, or is absent. Treatment of arthritic rats with peptide p30A resulted in remission of the arthritic condition and produced weight gain.

=> s 142 and peptidomimetics
L45 1 L42 AND PEPTIDOMIMETICS

=> d 145 cbib abs

L45 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
2005:1130891 Document No. 143:399818 CD23-binding peptides and peptidomimetics for treatment of autoimmune and inflammatory disorders. Mossalayi, Mohammad Djavad; Moynet, Daniel ; Vincendeau, Philippe; Rambert, Jerome; Self, Christopher R. (Universite Bordeaux 2, Fr.). PCT Int. Appl. WO 2005098435 A2 20051020, 59 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-IB1133 20050405. PRIORITY: EP 2004-290899 20040405.

AB The invention describes compds. comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compds. of the invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1-X2-X3-X4-X5-X6-X7-X8, wherein: X1 is Phe, or is absent; X2 is His or Ala; X3 is Glu, Ser, Ala, Asn, Lys, or Cys; X4 is Asn, Phe, Gln, Pro, Ser, or Ala; X5 is Trp; X6 is Pro, Arg, Glu, Gly, Cys, or Lys; X7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8 is Phe, Gly, or is absent. Treatment of arthritic rats with peptide p30A resulted in remission of the arthritic condition and produced weight gain.

=> dup remove 143
PROCESSING COMPLETED FOR L43
L46 41 DUP REMOVE L43 (45 DUPLICATES REMOVED)

=> s 146 and autoimmune
L47 7 L46 AND AUTOIMMUNE

=> d 147 1-7 cbib abs

L47 ANSWER 1 OF 7 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN 2006:243485 Document No.: PREV200600252032. Therapeutic agents and methods of use thereof for the modulation of angiogenesis. Olson, Gary L. [Inventor];

Self, Christopher [Inventor]; Lee, Lily [Inventor]; Cook, Charles Michael [Inventor]; Birktoft, Jens [Inventor]. Mountainside, NJ USA. ASSIGNEE: Praecis Pharmaceuticals, Inc.. Patent Info.: US 06919307 20050719. Official Gazette of the United States Patent and Trademark Office Patents, (JUL 19 2005)

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB The present invention provides methods of treating a parasitic infection, a lymphoid malignancy or an autoimmune disorder in a subject by administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising a MetAP-2 inhibitory core coupled to a peptide.

L47 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
2005:1130891 Document No. 143:399818 CD23-binding peptides and peptidomimetics for treatment of autoimmune and inflammatory disorders. Mossalayi, Mohammad Djavad; Moynet, Daniel; Vincendeau, Philippe; Rambert, Jerome; Self, Christopher R. (Universite Bordeaux 2, Fr.). PCT Int. Appl. WO 2005098435 A2 20051020, 59 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-IB1133 20050405. PRIORITY: EP 2004-290899 20040405.

AB The invention describes compds. comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compds. of the invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1-X2- X3-X4-X5-X6-X7-X8, wherein: X1 is Phe, or is absent; X2 is His or Ala; X3 is Glu, Ser, Ala, Asn, Lys, or Cys; X4 is Asn, Phe, Gln, Pro, Ser, or Ala; X5 is Trp; X6 is Pro, Arg, Glu, Gly, Cys, or Lys; X7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8 is Phe, Gly, or is absent. Treatment of arthritic rats with peptide p30A resulted in remission of the arthritic condition and produced weight gain.

L47 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
2005:238675 Document No. 142:317077 Preparation of amino acid derivatives as methionine aminopeptidase-2 inhibitors. Olson, Gary L.; Self, Christopher; Lee, Lily; Cook, Charles Michael; Birktoft, Jens; Morgan, Barry; Arico-Muendel, Christopher C. (Praecis Pharmaceuticals Inc., USA). U.S. Pat. Appl. Publ. US 20050059585 A1 20050317, 51 pp., Cont.-in-part of U.S. Ser. No. 138,935. (English). CODEN: USXXCO. APPLICATION: US 2003-429174 20030502. PRIORITY: US 2000-704251 20001101; US 2001-972772 20011005; US 2001-1945 20011101; US 2002-138935 20020502.

AB Compds. A-W-CONR1-Xn-CR3R4-Z-P [A is a Met-AP2 inhibitory core; W = O or NR2; R1, R2 = H or alkyl; X = alkylene or substituted alkylene; n = 0 or 1; R3, R4 = H, (un)substituted alkyl, aryl or heteroaryl; R3R4 = alkylene or R3R4C is a carbocyclic or heterocyclic group; Z = CO or alkylene-CO and P is a peptide comprising 1.apprx.100 amino acid residues attached at its amino terminus to Z or a group OR5 or NR6R7, where R5, R6, R7 are H, (un)substituted alkyl or azacycloalkyl or R6R7N = (un)substituted heterocyclyl; or Z = O, NR8 (R8 is H or alkyl), alkylene-CO or alkylene-NR8 and P is H, alkyl or a peptide comprising 1.apprx.100 amino acid residues attached at its carboxy terminus to Z] were prepared for treating an angiogenic disease, e.g.,

cancer. Title angiogenesis inhibitor compds. have excellent methionine aminopeptidase-2 (MetAP2) inhibitory activity and are able to inhibit endothelial cell growth at the picomolar range. Thus, Q-CO-D-Val-NH2 (Q is the alc. derived from fumagillin) was prepared via amidation reaction and evaluated for inhibition of SR cell proliferation.

L47 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

2003:455053 Document No. 139:7179 Preparation of compounds comprising a methionine aminopeptidase 2 (MetAP-2) inhibitory core coupled to a peptide for modulation of angiogenesis. Olson, Gary L.; Self, Christopher; Lee, Lily; Cook, Charles Michael; Birktoft, Jens; Morgan, Barry; Arico-Muendel, Christopher C. (Praecis Pharmaceuticals Inc., USA). U.S. Pat. Appl. Publ. US 20030109671 A1 20030612, 48 pp., Cont.-in-part of U.S. Ser. No. 1,945. (English). CODEN: USXXCO. APPLICATION: US 2002-138935 20020502. PRIORITY: US 2000-704251 20001101; US 2001-972772 20011005; US 2001-1945 20011101.

AB The invention provides angiogenesis inhibitor compds. A-W-CONR1-Xn-CR3R4-Z-P [A is a Met-AP-2 inhibitory core; W is O or NR2; R1, R2 are H or alkyl; X is alkylene or substituted alkylene; n is 0 or 1; R3, R4 are H, (un)substituted alkyl or (hetero)aryl; or CR3R4 is carbocyclic, heterocyclic, or alkylene; Z is CO or alkylene-CO and P is a peptide comprising 1 to about 100 amino acid residues attached at its amino terminus to Z or a group OR5 or NR6R7, where R5-R7 are H, alkyl, (un)substituted alkyl or azacycloalkyl or NR6R7 is (un)substituted heterocyclyl; or Z is O, NR6 (R8 = H or alkyl), alkylene-O, or alkylene-NR8 and P is H, alkyl or a peptide consisting of 1 to about 100 amino acid residues attached at its carboxy terminus to Z] comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compns. comprising the angiogenesis inhibitor compds. Thus, (3R,4S,5S,6R)-5-methoxy-4-[(2R, 3R)-2-methyl-3-(3-methylbut-2-enyl)oxiranyl]-1-oxaspiro[2.5]oct-6-ylcarbonyl-L-valine Me ester, prepared by acylation of L-valine Me ester hydrochloride, showed IC50 = 4.7 nM for inhibition of MetAP-2.

L47 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

2002:965105 Document No. 138:33374 Therapeutic agents and methods of use thereof for the modulation of angiogenesis. Olson, Gary L.; Self, Christopher; Lee, Lily; Cook, Charles Michael; Birktoft, Jens (Praecis Pharmaceuticals Inc., USA). U.S. Pat. Appl. Publ. US 20020193298 A1 20021219, 38 pp., Cont.-in-part of U. S. Ser. No. 704,251. (English). CODEN: USXXCO. APPLICATION: US 2001-972772 20011005. PRIORITY: US 2000-704251 20001101.

AB The present invention provides angiogenesis inhibitor compds. comprising a MetAP-2 (methionine aminopeptidase-2)-inhibitory fumagillin core coupled to a peptide, as well as pharmaceutical compns. comprising the angiogenesis inhibitor compds. and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compds. of the invention.

L47 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

2002:794303 Document No. 137:311201 Preparation of amino acid compounds containing the fumagillin core for the modulation of angiogenesis. Olson, Gary L.; Self, Christopher; Lee, Lily; Cook, Charles Michael; Birktoft, Jens; Morgan, Barry; Arico-muendel, Christopher C. (Praecis Pharmaceuticals Inc., USA). U.S. Pat. Appl. Publ. US 20020151493 A1 20021017, 47 pp., Cont.-in-part of U. S. Ser. No. 972,772. (English). CODEN: USXXCO. APPLICATION: US 2001-1945 20011101. PRIORITY: US 2000-704251 20001101; US 2001-972772 20011005.

AB Compds. A-W-CONR1-Xn-CR3R4-Z-P [A is a Met-AP2 inhibitory core; W = O or NR2; R1, R2 = H or alkyl; X = alkylene or substituted alkylene; n = 0 or

1; R3, R4 = H, (un)alkyl, aryl or heteroaryl; R3R4 = alkylene or R3R4C is a carbocyclic or heterocyclic group; Z = CO or alkylene-CO-; P is a peptide comprising 1.apprx.100 amino acid residues attached at its amino terminus to Z or a group OR5 or NR6R7, where R5, R6, R7 are H, (un)substituted alkyl or azacycloalkyl or R6R7N = (un)substituted heterocyclyl; or Z = O, NR8, alkylene-O, alkylene-NR8, where R8 = H or alkyl and P = H, alkyl, or a peptide] were prepared for treating an angiogenic disease, e.g., cancer. Title angiogenesis inhibitor compds. have excellent MetAP2 inhibitory activity and are able to inhibit endothelial cell growth at the picomolar range. Thus, Q-CO-D-Val-Me (Q is the alc. derived from fumagillin) was prepared via amidation reaction and showed IC50 = 4.7 nM in MetAP2 assay.

L47 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 2002:408668 Document No. 136:402029 Preparation of amino acid compounds containing the fumagillin core for the modulation of angiogenesis. Olson, Gary L.; Self, Christopher; Lee, Lily; Cook, Charles Michael; Birktoft, Jens (Praecis Pharmaceuticals Inc., USA). PCT Int. Appl. WO 2002042295 A2 20020530, 98 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US46086 20011101. PRIORITY: US 2000-704251 20001101; US 2001-972772 20011005.

AB Compds. A-W-CONR1-Xn-CR3R4-Z-P [A is a Met-AP2 inhibitory core; W = O or NR2; R1, R2 = H or alkyl; X = alkylene or substituted alkylene; n = 0 or 1; R3, R4 = H, (un) alkyl, aryl or heteroaryl; R3R4 = alkylene or R3R4C is a carbocyclic or heterocyclic group; Z = CO or alkylene-CO-; P is a peptide comprising 1.apprx.100 amino acid residues attached at its amino terminus to Z or a group OR5 or NR6R7, where R5, R6, R7 are H, (un)substituted alkyl or azacycloalkyl or R6R7N = (un)substituted heterocyclyl] were prepared for treating an angiogenic disease, e.g., cancer. Title angiogenesis inhibitor compds. have excellent MetAP2 inhibitory activity and are able to inhibit endothelial cell growth at the picomolar range. Thus, Q-CO-D-Val-Me (Q is the alc. derived from fumagillin) was prepared via amidation reaction and showed IC50 = 4.7 nM in MetAP2 assay.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	201.07	201.28
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.40	-10.40

STN INTERNATIONAL LOGOFF AT 11:10:29 ON 21 AUG 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID: SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved
NEWS 26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998

NEWS 28 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 29 AUG 15 CAplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:59:43 ON 24 AUG 2008

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 16:00:02 ON 24 AUG 2008

FILE 'EMBASE' ENTERED AT 16:00:02 ON 24 AUG 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:00:02 ON 24 AUG 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 16:00:02 ON 24 AUG 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 16:00:02 ON 24 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s iNOS inhibitor
L1 4776 INOS INHIBITOR

=> s l1 and "Ac-W-N-COOH"
L2 0 L1 AND "AC-W-N-COOH"

=> s 11 and "WN"
L3 0 L1 AND "WN"

=> s 11 and "acetyl-amino-indoylbutyric acid"
L4 0 L1 AND "ACETYL-AMINO-INDOYLBUTYRIC ACID"

=> s 11 and butyric acid
L5 0 L1 AND BUTYRIC ACID

=> S 11 and indoYL
L6 0 L1 AND INDOYL

=> s l1 and "HENWPS"
L7 0 L1 AND "HENWPS"

=> s l1 and AcwnCOOH
L8 0 L1 AND ACWNCOOH

=> s l1 and aceytyl-arginine-tryptophan
L9 0 L1 AND ACEYTYL-ARGININE-TRYPTOPHAN

=> s l1 and peptidomimetics
L10 0 L1 AND PEPTIDOMIMETICS

=> s l1 adn "FHENWPT"
MISSING OPERATOR L1 ADN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1 and "FHENWPT"
L11 0 L1 AND "FHENWPT"

=> s l1 and "FHENWPS"
L12 0 L1 AND "FHENWPS"

=> s l1 and HENWS
L13 0 L1 AND HENWS

=> s l1 and peptide
L14 135 L1 AND PEPTIDE

=> s l14 and "FHEQWPS"
L15 0 L14 AND "FHEQWPS"

=> s l14 and di-peptide
L16 0 L14 AND DI-PEPTIDE

=> s l1 and "FHEFWPT"
L17 0 L1 AND "FHEFWPT"

=> dup remove l14
PROCESSING COMPLETED FOR L14
L18 54 DUP REMOVE L14 (81 DUPLICATES REMOVED)

=> d l18 1-54 cbib

L18 ANSWER 1 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN
2008:285817 Document No. 148:306411 CC chemokine receptor 2 inhibitors for
inhibition of influenza virus-induced pulmonary immune pathology and drug
screening. Gunn, Michael Dee (Duke University, USA). PCT Int. Appl. WO
2008027377 A1 20080306, 102pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT,
AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE,
DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT,
LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES,
FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN,
TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-US18914
20070829. PRIORITY: US 2006-841140P 20060829.

L18 ANSWER 2 OF 54 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights
reserved on STN
2008224558 EMBASE Identification of the functional activity of the [A-4]

amelogenin gene splice product in newborn mouse ameloblasts.
Jacob, Stanca; Veis, Arthur (correspondence). Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States. aveis@northwestern.edu.
Bone Vol. 42, No. 6, pp. 1072-1079 Jun 2008.
Refs: 28.
ISSN: 8756-3282. CODEN: BONEDL
S 8756-3282(08)00070-7. Pub. Country: United States. Language: English.
Summary Language: English.
Entered STN: 20080606. Last Updated on STN: 20080606

L18 ANSWER 3 OF 54 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
2008250240 EMBASE Nitric oxide signaling pathway in the anti-convulsant effect of adenosine against pentylenetetrazol-induced seizure threshold in mice.
Akula, Kiran Kumar; Dhir, Ashish; Kulkarni, S.K. (correspondence). Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India. skpu@yahoo.com.
European Journal of Pharmacology Vol. 587, No. 1-3, pp. 129-134 10 Jun 2008.
Refs: 38.
ISSN: 0014-2999. CODEN: EJPHAZ
S 0014-2999(08)00378-6. Pub. Country: Netherlands. Language: English.
Summary Language: English.
Entered STN: 20080716. Last Updated on STN: 20080716

L18 ANSWER 4 OF 54 MEDLINE on STN DUPLICATE 1
2008035734. PubMed ID: 18023291. Thrombin peptide TP508 prevents nitric oxide mediated apoptosis in chondrocytes in the endochondral developmental pathway. Zhong M; Wike L J; Ryaby J T; Carney D H; Boyan B D; Schwartz Z. (Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech, Atlanta, GA 30332-0363, USA.) Biochimica et biophysica acta, (2008 Jan) Vol. 1783, No. 1, pp. 12-22. Electronic Publication: 2007-11-20. Journal code: 0217513. ISSN: 0006-3002. Pub. country: Netherlands. Language: English.

L18 ANSWER 5 OF 54 MEDLINE on STN DUPLICATE 2
2007460375. PubMed ID: 17604095. Effects of manipulating the nitric oxide/cyclic GMP pathway on bovine oocyte meiotic resumption in vitro. Bilodeau-Goeseels Sylvie. (Agriculture and Agri-Food Canada, Lethbridge Research Centre, Lethbridge, Alberta, Canada.. goeseelss@agr.gc.ca) . Theriogenology, (2007 Sep 15) Vol. 68, No. 5, pp. 693-701. Electronic Publication: 2007-06-29. Journal code: 0421510. ISSN: 0093-691X. Pub. country: United States. Language: English.

L18 ANSWER 6 OF 54 MEDLINE on STN DUPLICATE 3
2007614881. PubMed ID: 17558353. Activated protein C suppresses adrenomedullin and ameliorates lipopolysaccharide-induced hypotension. Gupta Akanksha; Berg David T; Gerlitz Bruce; Richardson Mark A; Galbreath Elizabeth; Syed Samreen; Sharma Avadhesh C; Lowry Stephen F; Grinnell Brian W. (Division of Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0444, USA.) Shock (Augusta, Ga.), (2007 Oct) Vol. 28, No. 4, pp. 468-76. Journal code: 9421564. ISSN: 1073-2322. Pub. country: United States. Language: English.

L18 ANSWER 7 OF 54 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
2007:516730 The Genuine Article (R) Number: 157TW. Role of nitric oxide in alpha-melanocyte-stimulating hormone-induced hypotension in the nucleus tractus solitarius of the spontaneously hypertensive rats. Tai, Ming-Hong;

Weng, Wen-Tsan; Lo, Wan-Chen; Chan, Julie Y. H.; Lin, Che-Jen; Lam, Hing-Chung; Tseng, Ching-Jiunn (Reprint). Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan (Reprint); Kaohsiung Med Univ, Grad Inst Biochem, Kaohsiung, Taiwan; Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan. cjtse@vghks.gov.tw. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (MAY 2007) Vol. 321, No. 2, pp. 455-461. ISSN: 0022-3565. Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA. Language: English.

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L18 ANSWER 8 OF 54 MEDLINE on STN DUPLICATE 4
2007425980. PubMed ID: 17487460. The role of iNOS-derived NO in the antihypertrophic actions of B-type natriuretic peptide in neonatal rat cardiomyocytes. Wang Tiannan; Yan Ming; Li Jieyue; Zheng Xiaoxiang. (Department of Biomedical Engineering, Zhejiang University (Yuquan Campus), Hangzhou 310027, P.R. China.) Molecular and cellular biochemistry, (2007 Aug) Vol. 302, No. 1-2, pp. 169-77. Electronic Publication: 2007-05-09. Journal code: 0364456. ISSN: 0300-8177. Pub. country: Netherlands. Language: English.

L18 ANSWER 9 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN
2007:908756 Document No. 147:314386 Effects of fucoidan on neuronal cell proliferation: association with NO production through the iNOS pathway. Lee, Hye-Rim; Do, Hang; Lee, Sung-Ryul; Sohn, Eun-Soo; Pyo, Suhkneung; Son, Eunwha (College of Pharmacy, Sungkyunkwan University, Gyeonggi, 440-746, S. Korea). Journal of Food Science and Nutrition, 12(2), 74-78 (English) 2007. CODEN: JFSNFW. ISSN: 1226-332X. Publisher: Korean Society of Food Science and Nutrition.

L18 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN
2006:77052 Document No. 144:156752 Semi-directional drug delivering stents. Raze, Brian; Tseng, David (Medtronic Vascular, Inc., USA). U.S. Pat. Appl. Publ. US 20060020329 A1 20060126, 9 pp. (English). CODEN: USXXCO. APPLICATION: US 2005-131454 20050516. PRIORITY: US 2004-574898P 20040526.

L18 ANSWER 11 OF 54 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
2006:338474 Document No.: PREV200600337033. L-4F, an apo A-I mimetic peptide, prevents lipopolysaccharide-induced changes in vascular function. Zhang, Zhenghao [Reprint Author]; Dai, Lijun; Gupta, Himanshu; Honavar, Jaideep. Univ Alabama, Birmingham, AL 35294 USA. FASEB Journal, (MAR 7 2006) Vol. 20, No. 5, Part 2, pp. A1073. Meeting Info.: Experimental Biology 2006 Meeting. San Francisco, CA, USA. April 01 -05, 2006. Amer Assoc Anatomists; Amer Physiol Soc; Amer Soc Biochem & Mol Biol; Amer Soc Investigat Pathol; Amer Soc Nutr; Amer Soc Pharmacol & Expt Therapeut. CODEN: FAJOEC. ISSN: 0892-6638. Language: English.

L18 ANSWER 12 OF 54 MEDLINE on STN DUPLICATE 5
2006209893. PubMed ID: 16480717. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Ryu Jae K; McLarnon James G. (Department of Pharmacology and Therapeutics, Faculty of Medicine, The University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, Canada V6T 1Z3.) Experimental neurology, (2006 Apr) Vol. 198, No. 2, pp. 552-7. Electronic Publication: 2006-02-09. Journal code: 0370712. ISSN: 0014-4886. Pub. country: United States. Language: English.

L18 ANSWER 13 OF 54 MEDLINE on STN DUPLICATE 6
2006370927. PubMed ID: 16786102. Effect of adrenomedullin on the activity of barosensitive neurons in the rostral ventrolateral medulla of rats. Fan Ming-Xin; Li Xia; Wang Jin; Cao Yin-Xiang; Shen Lin-Lin; Zhu Da-Nian.

(Department of Physiology and Pathophysiology, Shanghai Medical College of Fudan University, Shanghai 200032, China. E-mail: dnzhu@ shmu.edu.cn.)
Sheng li xue bao : [Acta physiologica Sinica], (2006 Jun 25) Vol. 58, No. 3, pp. 193-200. Journal code: 20730130R. ISSN: 0371-0874. Pub. country: China. Language: English.

L18 ANSWER 14 OF 54 MEDLINE on STN
2006229151. PubMed ID: 16490313. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Esposito Giuseppe; De Filippis Daniele; Maiuri Maria Chiara; De Stefano Daniela; Carnuccio Rosa; Iuvone Teresa. (Department of Experimental Pharmacology, Faculty of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.) Neuroscience letters, (2006 May 15) Vol. 399, No. 1-2, pp. 91-5. Electronic Publication: 2006-02-21. Journal code: 7600130. ISSN: 0304-3940. Pub. country: Ireland. Language: English.

L18 ANSWER 15 OF 54 MEDLINE on STN DUPLICATE 7
2006400258. PubMed ID: 16621629. Nitric oxide inhibits neutrophil migration by a mechanism dependent on ICAM-1: role of soluble guanylate cyclase. Dal Secco Daniela; Moreira Ana P; Freitas Andressa; Silva Joao S; Rossi Marcos A; Ferreira Sergio H; Cunha Fernando Q. (Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Avenida Bandeirantes, 3900, 14049-900-Ribeirao Preto, Sao Paulo, Brazil.) Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society, (2006 Aug) Vol. 15, No. 1, pp. 77-86. Electronic Publication: 2006-04-18. Journal code: 9709307. ISSN: 1089-8603. Pub. country: United States. Language: English.

L18 ANSWER 16 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN
2005:1354712 Document No. 144:94350 A method of improving the medical treatment of pain. Christgau, Stephan; Hansen, Christian; Nilsson, Henrik (Osteologix A/S, Den.). PCT Int. Appl. WO 2005123192 A2 20051229, 34 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-DK401 20050617. PRIORITY: DK 2004-947 20040617.

L18 ANSWER 17 OF 54 MEDLINE on STN DUPLICATE 8
2005067905. PubMed ID: 15684620. Inhibition of IFN-gamma-stimulated proinflammatory cytokines by vasoactive intestinal peptide (VIP) correlates with increased survival of *Salmonella enterica* serovar typhimurium phoP in murine macrophages. Foster Neil; Hulme Scott D; Barrow Paul A. (Department of Environmental Microbiology, Institute for Animal Health, Compton Laboratory, Compton, Newbury, Berkshire RG20 7NN, United Kingdom.) Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, (2005 Jan) Vol. 25, No. 1, pp. 31-42. Journal code: 9507088. ISSN: 1079-9907. Pub. country: United States. Language: English.

L18 ANSWER 18 OF 54 MEDLINE on STN DUPLICATE 9
2004338859. PubMed ID: 15240796. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. Wang Qinwen; Rowan Michael J; Anwyl Roger. (Department of

Physiology, Trinity College, Dublin 2, Ireland.) The Journal of neuroscience : the official journal of the Society for Neuroscience, (2004 Jul 7) Vol. 24, No. 27, pp. 6049-56. Journal code: 8102140. E-ISSN: 1529-2401. Pub. country: United States. Language: English.

L18 ANSWER 19 OF 54 MEDLINE on STN DUPLICATE 10
2004571007. PubMed ID: 15501530. Urotensin-II activates L-arginine/nitric oxide pathway in isolated rat aortic adventitia. Lin Li; Ding Wen-Hui; Jiang Wei; Zhang Yong-Gang; Qi Yong-Fen; Yuan Wen-Jun; Tang Chao-Shu. (Department of Physiology, Second Military Medical University, Shanghai 200433, PR China.. linlil@msu.edu) . Peptides, (2004 Nov) Vol. 25, No. 11, pp. 1977-84. Journal code: 8008690. ISSN: 0196-9781. Pub. country: United States. Language: English.

L18 ANSWER 20 OF 54 MEDLINE on STN
2004411410. PubMed ID: 15316672. Fibronectin fragments elevate nitric oxide (NO) and inducible NO synthetase (iNOS) levels in bovine cartilage and iNOS inhibitors block fibronectin fragment mediated damage and promote repair. Pichika R; Homandberg G A. (Department of Biochemistry, Rush Medical College at Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, Chicago, IL 60612-3864, USA.) Inflammation research : official journal of the European Histamine Research Society ... [et al.], (2004 Aug) Vol. 53, No. 8, pp. 405-12. Electronic Publication: 2004-08-10. Journal code: 9508160. ISSN: 1023-3830. Pub. country: Switzerland. Language: English.

L18 ANSWER 21 OF 54 MEDLINE on STN DUPLICATE 11
2004435708. PubMed ID: 15341183. Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. Saez T Estefania; Pehar Mariana; Vargas Marcelo; Barbeito Luis; Maccioni Ricardo B. (Millennium Institute for Advanced Studies CBB, Faculty of Sciences, University of Chile, Las Encinas 3370, Nunoa, Santiago, Chile.) In vivo (Athens, Greece), (2004 May-Jun) Vol. 18, No. 3, pp. 275-80. Journal code: 8806809. ISSN: 0258-851X. Pub. country: Greece. Language: English.

L18 ANSWER 22 OF 54 MEDLINE on STN DUPLICATE 12
2004223362. PubMed ID: 15120566. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Patel Hemal H; Hsu Anna K; Gross Garrett J. (Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.. hepatel@ucsd.edu) . Life sciences, (2004 May 28) Vol. 75, No. 2, pp. 129-40. Journal code: 0375521. ISSN: 0024-3205. Pub. country: England: United Kingdom. Language: English.

L18 ANSWER 23 OF 54 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
2005:504455 Document No.: PREV200510300120. Mediation of stromal swelling following corneal epithelial trauma. Velasquez, L. M. [Reprint Author]; Klyce, S. D.; Karon, M. D.; Courville, C. B.. Louisiana State Univ, Ctr Eye, New Orleans, LA 70112 USA. IOVS, (APR 2004) Vol. 45, No. Suppl. 1, pp. U129.
Meeting Info.: Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology. Ft Lauderdale, FL, USA. April 24 -29, 2004. Assoc Res Vis & Ophthalmol.
CODEN: IOVSDA. ISSN: 0146-0404. Language: English.

L18 ANSWER 24 OF 54 MEDLINE on STN
2004186515. PubMed ID: 15081250. Bone marrow-derived versus parenchymal sources of inducible nitric oxide synthase in experimental autoimmune encephalomyelitis. Zehntner Simone P; Bourbonniere Lyne; Hassan-Zahraee Mina; Tran Elise; Owens Trevor. (Neuroimmunology Unit, Montreal Neurological Institute, 3801 University Street, Montreal, QC, Canada H3A 2B4.) Journal of neuroimmunology, (2004 May) Vol. 150, No. 1-2, pp. 70-9.

Journal code: 8109498. ISSN: 0165-5728. Pub. country: Netherlands.
Language: English.

L18 ANSWER 25 OF 54 MEDLINE on STN DUPLICATE 13
2004050610. PubMed ID: 14751408. Potentiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide. Moezi Leila; Rezayat Mehdi; Samini Morteza; Shafaroodi Hamed; Mehr Shahram Ejtemaie; Ebrahimkhani Mohammad R; Dehpour Ahmad R. (Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O.Box 13145-784, Tehran, Iran.) European journal of pharmacology, (2004 Feb 13) Vol. 486, No. 1, pp. 53-9. Journal code: 1254354. ISSN: 0014-2999. Pub. country: Netherlands. Language: English.

L18 ANSWER 26 OF 54 MEDLINE on STN DUPLICATE 14
2004286098. PubMed ID: 14977629. Carboxypeptidase-mediated enhancement of nitric oxide production in rat lungs and microvascular endothelial cells. Hadkar Vaishali; Sangsree Sakonwun; Vogel Stephen M; Brovkovich Viktor; Skidgel Randal A. (Department of Pharmacology, University of Illinois College of Medicine, Chicago, 60612, USA.) American journal of physiology. Lung cellular and molecular physiology, (2004 Jul) Vol. 287, No. 1, pp. L35-45. Electronic Publication: 2004-02-20. Journal code: 100901229. ISSN: 1040-0605. Pub. country: United States. Language: English.

L18 ANSWER 27 OF 54 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
2004261769 EMBASE Carboxypeptidase-mediated enhancement of nitric oxide production in rat lungs and microvascular endothelial cells. Hadkar, Vaishali; Sangsree, Sakonwun; Vogel, Stephen M.; Brovkovich, Viktor; Skidgel, Randal A. (correspondence). Department of Pharmacology, Univ. of Illinois Coll. of Medicine, Chicago, IL 60612, United States. rskidgel@uic.edu. Skidgel, Randal A. (correspondence). Department of Anesthesiology, Univ. of Illinois Coll. of Medicine, Chicago, IL 60612, United States. rskidgel@uic.edu. Skidgel, Randal A. (correspondence). Dept. of Pharmacology (m/c 868), Univ. of Illinois Coll. of Medicine, 835 S. Wolcott, Chicago, IL 60612, United States. rskidgel@uic.edu. American Journal of Physiology - Lung Cellular and Molecular Physiology Vol. 287, No. 1 31-1, pp. L35-L45 Jul 2004.
Refs: 76.
ISSN: 1040-0605. CODEN: APLPE7
Pub. Country: United States. Language: English. Summary Language: English.
Entered STN: 20040715. Last Updated on STN: 20040715

L18 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN
2003:300915 Document No. 138:302642 Inducible nitric oxide synthase inhibitors as vaccine adjuvants. Thomsen, Lindy Louise (Glaxo Group Limited, UK). PCT Int. Appl. WO 2003030935 A2 20030417, 33 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-GB4365 20020926.
PRIORITY: GB 2001-24022 20011005.

L18 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN
2003:717498 Document No. 139:235421 Pulmonary vasodilator surfactant compositions and method of use. Ahmad, Magdy (Board of Trustees of Michigan State University, USA). U.S. Pat. Appl. Publ. US 20030170223 A1 20030911, 16 pp., which (English). CODEN: USXXCO. APPLICATION: US

2003-356062 20030131. PRIORITY: US 2002-353149P 20020201; US 2002-376293P 20020429.

L18 ANSWER 30 OF 54 MEDLINE on STN
2003249838. PubMed ID: 12773701. Regulation of vascular endothelial growth factor gene expression in murine macrophages by nitric oxide and hypoxia. Ramanathan Madhuri; Giladi Avi; Leibovich S Joseph. (Department of Cell Biology and Molecular Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103, USA.) Experimental biology and medicine (Maywood, N.J.), (2003 Jun) Vol. 228, No. 6, pp. 697-705. Journal code: 100973463. ISSN: 1535-3702. Pub. country: United States. Language: English.

L18 ANSWER 31 OF 54 MEDLINE on STN DUPLICATE 15
2003262404. PubMed ID: 12787051. Nitric oxide produced by a novel nitric oxide synthase isoform is necessary for gonadotropin-releasing hormone-induced growth hormone secretion via a cGMP-dependent mechanism. Uretsky A D; Weiss B L; Yunker W K; Chang J P. (Departments of Biological Sciences and Medicine, University of Alberta, Edmonton, Alberta, Canada.) Journal of neuroendocrinology, (2003 Jul) Vol. 15, No. 7, pp. 667-76. Journal code: 8913461. ISSN: 0953-8194. Pub. country: United Kingdom. Language: English.

L18 ANSWER 32 OF 54 MEDLINE on STN DUPLICATE 16
2003219387. PubMed ID: 12740598. Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction. Tran M H; Yamada K; Nakajima A; Mizuno M; He J; Kamei H; Nabeshima T. (Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan.. tnabeshi@med.nagoya-u.ac.jp) . Molecular psychiatry, (2003 Apr) Vol. 8, No. 4, pp. 407-12. Journal code: 9607835. ISSN: 1359-4184. Pub. country: United Kingdom. Language: English.

L18 ANSWER 33 OF 54 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
2004:123873 Document No.: PREV200400116906. Peroxynitrite modulates in vitro activity of proteasome from liver and in cultured hepatoma cells. Osna, Natalia A. [Reprint Author]; Haorah, James [Reprint Author]; Wyatt, Todd [Reprint Author]; Donohue, Terrence M. Jr. [Reprint Author]. UNMC, Omaha, NE, USA. Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp. 392A. print. Meeting Info.: 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA. October 24-28, 2003. American Association for the Study of Liver Diseases. ISSN: 0270-9139 (ISSN print). Language: English.

L18 ANSWER 34 OF 54 MEDLINE on STN DUPLICATE 17
20033391833. PubMed ID: 12926985. Effect of radiation on cAMP, cGMP and Ca(2+)(i) pathways and their interactions in rat distal colon. Morel E; Dublineau I; Griffiths N M. (Institut de Radioprotection et de Surete Nucleaire, Departement de Protection de la sante de l'Homme et de Dosimetrie, Section Autonome de Radiobiologie Appliquee a la Medecine, IRSN, Fontenay aux Roses Cedex, France.) Radiation research, (2003 Sep) Vol. 160, No. 3, pp. 263-72. Journal code: 0401245. ISSN: 0033-7587. Pub. country: United States. Language: English.

L18 ANSWER 35 OF 54 MEDLINE on STN DUPLICATE 18
2002426256. PubMed ID: 12183331. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Akerman S; Williamson D J; Kaube H; Goadsby P J. (Headache Group, Institute of Neurology, Queen Square, London WC1N 3BG.) British journal of pharmacology, (2002 Sep)

Vol. 137, No. 1, pp. 62-8. Journal code: 7502536. ISSN: 0007-1188. Pub. country: England: United Kingdom. Language: English.

L18 ANSWER 36 OF 54 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
2001:350640 Document No.: PREV200100350640. Selective inhibition of human inducible nitric oxide synthase by S-alkyl-L-isothiocitrulline-containing dipeptides. Park, Jung-Min; Higuchi, Tsunehiko [Reprint author]; Kikuchi, Kazuya; Urano, Yasuteru; Hori, Hiroyuki; Nishino, Takeshi; Aoki, Junken; Inoue, Keizo; Nagano, Tetsuo. Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya, 467-3603, Japan. higuchi@phar.nagoya-cu.ac.jp; tlong@mol.f.u-tokyo.ac.jp. British Journal of Pharmacology, (April, 2001) Vol. 132, No. 8, pp. 1876-1882. print. CODEN: BJPCBM. ISSN: 0007-1188. Language: English.

L18 ANSWER 37 OF 54 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
2002:125495 The Genuine Article (R) Number: 519BV. Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. Tran M H; Yamada K; Olariu A; Mizuno M; Ren X H; Nabeshima T (Reprint). Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Nagoya, Aichi 4668560, Japan (Reprint). tnabeshi@med.nagoya-u.ac.jp. FASEB JOURNAL (27 APR 2001) Vol. 15, No. 6, pp. 1407-+. ISSN: 0892-6638. Publisher: FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA. Language: English.
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L18 ANSWER 38 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN
2001:583810 Document No. 135:286815 Amyloid β - peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. Tran, Manh Hung; Yamada, Kiyofumi; Olariu, Ana; Mizuno, Makoto; Ren, Xiu Hai; Nabeshima, Toshitaka (Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, 466-8560, Japan). FASEB Journal, 15(8), 1407-1409, 10.1096/fj.00-0719fje (English) 2001. CODEN: FAJOEC. ISSN: 0892-6638. Publisher: Federation of American Societies for Experimental Biology.

L18 ANSWER 39 OF 54 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
2002:19084 The Genuine Article (R) Number: 503JY. Interleukin-1 beta inhibits proinsulin conversion in rat beta-cells via a nitric oxide-dependent pathway. Zambre Y; Van Schravendijk C; Ling Z (Reprint). Free Univ Brussels, Diabet Res Ctr, Fac Med, Laarbeeklaan 103, B-1090 Brussels, Belgium (Reprint); Free Univ Brussels, Diabet Res Ctr, Fac Med, B-1090 Brussels, Belgium. HORMONE AND METABOLIC RESEARCH (NOV 2001) Vol. 33, No. 11, pp. 639-644. ISSN: 0018-5043. Publisher: GEORG THIEME VERLAG KG, RUDIGERSTR 14, D-70469 STUTTGART, GERMANY. Language: English.
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L18 ANSWER 40 OF 54 MEDLINE on STN DUPLICATE 19
2001556623. PubMed ID: 11564662. Antisense knockdown of inducible nitric oxide synthase inhibits the relaxant effect of VIP in isolated smooth muscle cells of the mouse gastric fundus. Dick J M; Van Molle W; Libert C; Lefebvre R A. (Heymans Institute of Pharmacology, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, B-9000 Ghent, Belgium.) British journal of pharmacology, (2001 Sep) Vol. 134, No. 2, pp. 425-33. Journal code: 7502536. ISSN: 0007-1188. Pub. country: England: United Kingdom. Language: English.

L18 ANSWER 41 OF 54 MEDLINE on STN DUPLICATE 20
2001100744. PubMed ID: 11196180. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Salvucci O; Carsana M; Bersani I; Tragni G; Anichini A. (Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.) Cancer research, (2001 Jan 1) Vol. 61, No. 1, pp. 318-26. Journal code: 2984705R. ISSN: 0008-5472. Pub. country: United States. Language: English.

L18 ANSWER 42 OF 54 MEDLINE on STN
2001094354. PubMed ID: 11123195. Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction. Fan Y P; Chakder S; Gao F; Rattan S. (Division of Gastroenterology and Hepatology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.) American journal of physiology. Gastrointestinal and liver physiology, (2001 Jan) Vol. 280, No. 1, pp. G32-42. Journal code: 100901227. ISSN: 0193-1857. Pub. country: United States. Language: English.

L18 ANSWER 43 OF 54 MEDLINE on STN DUPLICATE 21
2000412246. PubMed ID: 10928982. Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase. Ishii K; Muelhauser F; Liebl U; Picard M; Kuhl S; Penke B; Bayer T; Wiessler M; Hennerici M; Beyreuther K; Hartmann T; Fassbender K. (Department of Neurology, Mannheim, University of Heidelberg, Germany.) The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, (2000 Aug) Vol. 14, No. 11, pp. 1485-9. Journal code: 8804484. ISSN: 0892-6638. Pub. country: United States. Language: English.

L18 ANSWER 44 OF 54 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
2001:100271 Document No.: PREV200100100271. Thrombin modulates mast cell activity through nitric oxide pathway. Chistov, I. V. [Reprint author]; Umarova, B. A. [Reprint author]; Dugina, T. N. [Reprint author]; Strukova, S. M. [Reprint author]. Department of Human Physiology, Lomonosov Moscow State University, Moscow, Russia. Journal of Submicroscopic Cytology and Pathology, (July, 2000) Vol. 32, No. 3, pp. 458. print.
Meeting Info.: XIth International Vascular Biology Meeting. Geneva, Switzerland. September 05-09, 2000.
ISSN: 1122-9497. Language: English.

L18 ANSWER 45 OF 54 MEDLINE on STN DUPLICATE 22
2000394110. PubMed ID: 10899080. Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. Hamanaka I; Saito Y; Nishikimi T; Magaribuchi T; Kamitani S; Kuwahara K; Ishikawa M; Miyamoto Y; Harada M; Ogawa E; Kajiyama N; Takahashi N; Izumi T; Shirakami G; Mori K; Inobe Y; Kishimoto I; Masuda I; Fukuda K; Nakao K. (Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan 606-8507.) American journal of physiology. Heart and circulatory physiology, (2000 Jul) Vol. 279, No. 1, pp. H388-96. Journal code: 100901228. ISSN: 0363-6135. Pub. country: United States. Language: English.

L18 ANSWER 46 OF 54 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
2000:336108 Document No.: PREV200000336108. Characterization of nitrosated latency-associated peptide (LAP), the endogenous neutralizer of the iNOS-inhibitor cytokine transforming growth factor-beta1 (TGF-beta1). Zamora, Ruben [Reprint author]; Wink, David; Barcellos-Hoff, Mary Helen; Billiar, Timothy R. [Reprint author]; Vodovotz, Yoram [Reprint author]. Dept. of Surgery, University of

Pittsburgh, Pittsburgh, PA, USA. Nitric Oxide, (2000) Vol. 4, No. 3, pp. 313. print.

Meeting Info.: First International Conference on Biology, Chemistry, and Therapeutic Applications of Nitric Oxide. San Francisco, California, USA. June 03-07, 2000.

ISSN: 1089-8603. Language: English.

L18 ANSWER 47 OF 54 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN DUPLICATE 23

2000:893252 The Genuine Article (R) Number: 375QP. Pituitary adenylate cyclase-activating polypeptide prevents cytokine-induced cytotoxicity via inhibition of inducible nitric oxide synthase expression in beta TC cells. Sekiya K; Nagasaki H (Reprint); Ozaki N; Suzuki A; Miura Y; Oiso Y. Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (11 NOV 2000) Vol. 278, No. 1, pp. 211-216. ISSN: 0006-291X. Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA. Language: English.

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L18 ANSWER 48 OF 54 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

2000279347 EMBASE Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart.

Hamanaka, I.; Saito, Y. (correspondence); Nishikimi, T.; Magaribuchi, T.; Kamitani, S.; Kuwahara, K.; Ishikawa, M.; Miyamoto, Y.; Harada, M.; Ogawa, E.; Kajiyama, N.; Takahashi, N.; Izumi, T.; Shirakami, G.; Mori, K.; Inobe, Y.; Kishimoto, I.; Masuda, I.; Fukuda, K.; Nakao, K.. Dept. of Med. and Clinical Science, Kyoto Univ. Graduate Sch. of Med., 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. yssaito@kuhp.kyoto-u.ac.jp. American Journal of Physiology - Heart and Circulatory Physiology Vol. 279, No. 1 48-1, pp. H388-H396 2000.

Refs: 42.

ISSN: 0363-6135. CODEN: AJPPDI

Pub. Country: United States. Language: English. Summary Language: English. Entered STN: 20000831. Last Updated on STN: 20000831

L18 ANSWER 49 OF 54 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN

1999:714511 The Genuine Article (R) Number: 239FZ. Co-expression of inducible nitric oxide synthase and arginases in different human monocyte subsets. Apoptosis regulated by endogenous NO. Rouzaut A; Subira M L; de Miguel C; Domingo-de-Miguel E; Gonzalez A; Santiago E; Lopez-Moratalla N (Reprint). Univ Navarra, Dept Biochem, Apartado 177, E-31080 Pamplona, Spain (Reprint); Univ Navarra, Dept Biochem, E-31080 Pamplona, Spain; Univ Navarra, Dept Immunol, E-31080 Pamplona, Spain. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (21 SEP 1999) Vol. 1451, No. 2-3, pp. 319-333. ISSN: 0167-4889. Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS. Language: English.

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L18 ANSWER 50 OF 54 MEDLINE on STN DUPLICATE 24

2000126275. PubMed ID: 10657484. Calcitonin gene-related peptide causes long-term inhibition of contraction in rat thoracic aorta through a nitric oxide-dependent pathway. Lu L F; Fiscus R R. (Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, New Territory, Hong Kong, China.) Neuropeptides, (1999 Apr) Vol. 33, No. 2, pp. 145-54. Journal code: 8103156. ISSN: 0143-4179. Pub. country: SCOTLAND: United Kingdom. Language: English.

L18 ANSWER 51 OF 54 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on

STN

1998:433424 The Genuine Article (R) Number: ZR468. Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia. Okamoto H; Ito O; Roman R J; Hudetz A G (Reprint). Med Coll Wisconsin, Dept Anesthesiol, MEB Room 462C, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA (Reprint); Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA. STROKE (JUN 1998) Vol. 29, No. 6, pp. 1209-1218. ISSN: 0039-2499. Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA. Language: English.
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L18 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2008 ACS on STN

1998:737502 Document No. 130:138152 Induction of nitric oxide synthase by lipopolysaccharide inhalation enhances substance P-induced microvascular leakage in guinea-pigs. Ohuchi, Y.; Ichinose, M.; Miura, M.; Kageyama, N.; Tomaki, M.; Endoh, N.; Mashito, Y.; Sugiura, H.; Shirato, K. (First Dept of Internal Medicine, Tohoku University School of Medicine, Sendai, 980-8574, Japan). European Respiratory Journal, 12(4), 831-836 (English) 1998. CODEN: ERJOEI. ISSN: 0903-1936. Publisher: Munksgaard International Publishers Ltd..

L18 ANSWER 53 OF 54 MEDLINE on STN

1999005625. PubMed ID: 9789196. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes. Eue I; Kumar R; Dong Z; Killion J J; Fidler I J. (Department of Cell Biology, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA.) Journal of immunotherapy (Hagerstown, Md. : 1997), (1998 Sep) Vol. 21, No. 5, pp. 340-51. Journal code: 9706083. ISSN: 1524-9557. Pub. country: United States. Language: English.

L18 ANSWER 54 OF 54 MEDLINE on STN

1995330749. PubMed ID: 7541713. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Xie K; Huang S; Dong Z; Gutman M; Fidler I J. (Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.) Cancer research, (1995 Jul 15) Vol. 55, No. 14, pp. 3123-31. Journal code: 2984705R. ISSN: 0008-5472. Pub. country: United States. Language: English.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	158.31	158.52

STN INTERNATIONAL LOGOFF AT 16:08:24 ON 24 AUG 2008